Article

High C-reactive protein, high risk for AMD

Rotterdam, Netherlands-High blood levels of C-reactive protein may cause people to be at a higher risk of developing age-related macular degeneration (AMD).

Rotterdam, Netherlands-High blood levels of C-reactive protein may cause people to be at a higher risk of developing age-related macular degeneration (AMD).

Blood samples and photographs of the eyes were taken of 4,900 people at risk for AMD by Dutch researchers who followed the group for an average of 7.7 years.

Results were 658 diagnosed with AMD, 561 with initial stage AMD, and 97 with advanced AMD. As the C-reactive protein level increased above midpoint of the study group, that individual was more likely to develop AMD.

"A substance that can selectively inhibit C-reactive protein synthesis has not yet been developed, to our knowledge," wrote a team member from Erasmus Medical Center, Rotterdam. "Smoking and high body mass index increase C-reactive protein levels. Moderate alcohol intake, diets with low glycemic index, and statin [drugs} and multivitamin use reduce C-reactive protein levels."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.